HomeCompareCALT vs SBUX

CALT vs SBUX: Dividend Comparison 2026

CALT yields 5.00% · SBUX yields 2.84%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SBUX wins by $139.2K in total portfolio value· pulled ahead in Year 2
10 years
CALT
CALT
● Live price
5.00%
Share price
$40.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.8K
Annual income
$688.45
Full CALT calculator →
SBUX
SBUX
● Live price
2.84%
Share price
$86.72
Annual div
$2.46
5Y div CAGR
48.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$167.0K
Annual income
$71,136.45
Full SBUX calculator →

Portfolio growth — CALT vs SBUX

📍 SBUX pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCALTSBUX
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CALT + SBUX cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CALT pays
SBUX pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CALT
Annual income on $10K today (after 15% tax)
$425.00/yr
After 10yr DRIP, annual income (after tax)
$585.18/yr
SBUX
Annual income on $10K today (after 15% tax)
$241.12/yr
After 10yr DRIP, annual income (after tax)
$60,465.98/yr
At 15% tax rate, SBUX beats the other by $59,880.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CALT + SBUX for your $10,000?

CALT: 50%SBUX: 50%
100% SBUX50/50100% CALT
Portfolio after 10yr
$97.4K
Annual income
$35,912.46/yr
Blended yield
36.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on SBUX right now

CALT
Analyst Ratings
5
Hold
Consensus: Hold
Price Target
$39.50
-1.3% upside vs current
Range: $39.00 — $40.00
Altman Z
8.0
Piotroski
2/9
SBUX
Analyst Ratings
28
Buy
27
Hold
3
Sell
Consensus: Buy
Price Target
$104.00
+19.9% upside vs current
Range: $90.00 — $120.00
Altman Z
2.6
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CALT buys
0
SBUX buys
0
No recent congressional trades found for CALT or SBUX in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCALTSBUX
Forward yield5.00%2.84%
Annual dividend / share$2.00$2.46
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%48.3%
Portfolio after 10y$27.8K$167.0K
Annual income after 10y$688.45$71,136.45
Total dividends collected$6.0K$136.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusHoldBuy
Analyst price target$39.50$104.00

Year-by-year: CALT vs SBUX ($10,000, DRIP)

YearCALT PortfolioCALT Income/yrSBUX PortfolioSBUX Income/yrGap
1$11,200$500.00$11,121$420.68+$79.00CALT
2← crossover$12,507$523.36$12,548$648.40$41.00SBUX
3$13,929$546.22$14,440$1,013.98$511.00SBUX
4$15,473$568.51$17,068$1,617.30$1.6KSBUX
5$17,146$590.20$20,912$2,649.52$3.8KSBUX
6$18,957$611.24$26,875$4,499.29$7.9KSBUX
7$20,916$631.60$36,771$8,014.12$15.9KSBUX
8$23,031$651.27$54,542$15,197.11$31.5KSBUX
9$25,314$670.22$89,602$31,242.49$64.3KSBUX
10$27,774$688.45$167,011$71,136.45$139.2KSBUX

CALT vs SBUX: Complete Analysis 2026

CALTStock

Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment of the autoimmune renal disease immunoglobulin A nephropathy. The company's lead product candidate is Setanaxib, a NOX inhibitor that is in Phase 2b/3 clinical trial for the treatment of primary biliary cholangitis; and in Phase 2 clinical trial for the treatment of squamous cell carcinoma of the head and neck cancer and idiopathic pulmonary fibrosis, as well as for type 1 diabetic kidney disease. It also develops Budenofalk 3 mg oral capsules for the treatment of autoimmune hepatitis. The company was incorporated in 2004 and is headquartered in Stockholm, Sweden.

Full CALT Calculator →

SBUXConsumer Discretionary

Starbucks Corporation, together with its subsidiaries, operates as a roaster, marketer, and retailer of specialty coffee worldwide. The company operates through three segments: North America, International, and Channel Development. Its stores offer coffee and tea beverages, roasted whole beans and ground coffees, single serve products, and ready-to-drink beverages; and various food products, such as pastries, breakfast sandwiches, and lunch items. The company also licenses its trademarks through licensed stores, and grocery and foodservice accounts. The company offers its products under the Starbucks, Teavana, Seattle's Best Coffee, Evolution Fresh, Ethos, Starbucks Reserve, and Princi brands. As of October 3, 2021, it operated 16,826 company-operated and licensed stores in North America; and 17,007 company-operated and licensed stores internationally. The company was founded in 1971 and is based in Seattle, Washington.

Full SBUX Calculator →
📬

Get this CALT vs SBUX comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CALT vs SCHDCALT vs JEPICALT vs OCALT vs KOCALT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.